Rezolute Q1 FY2024 net loss $14.5M; RZ358 Phase 3 start planned before year-end

Rezolute, Inc.

2024-Q1 EPS reported -$0.28

Net loss of $14.5M for Q1 FY2024 vs $9.8M in same period last year.
R&D expenses $12.2M (up 58% YoY) due to increased clinical and manufacturing costs.
Cash and investments $106.9M as of Sep 30, 2023, down from $118.4M at Jun 30, 2023.
RZ358 granted EMA PRIME designation; Phase 3 sunRIZE study for congenital hyperinsulinism to initiate Q4 2023.
RZ402 Phase 2 enrollment in diabetic macular edema near completion; update expected before year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.